Hajar Sirous

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 17

Top Venues

Future medicinal chemistry

Viruses

International journal of molecular sciences

Food & function

Isfahan University of Medical Sciences (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Isfahan University of Medical Sciences

Iran

PHD :: department of medicinal chemistry, school of pharmacy and medical sciences

Publications

Behnaz Yazdani, Hajar Sirous, Simone Brogi, Vincenzo Calderone
Structure-Based High-Throughput Virtual Screening and Molecular Dynamics Simulation for the Discovery of Novel SARS-CoV-2 NSP3 Mac1 Domain Inhibitors. Viruses 15 (12) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry (2023)
Lorenzo Flori, Simone Brogi, Hajar Sirous, Vincenzo Calderone
Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes. International journal of molecular sciences 24 (8) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Lorenzo Flori, Simone Brogi, Hajar Sirous, Vincenzo Calderone
Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes. International journal of molecular sciences 24 (8) (2023)
Lorenzo Flori, Simone Brogi, Hajar Sirous, Vincenzo Calderone
Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes. International journal of molecular sciences 24 (8) (2023)
Behnaz Yazdani, Hajar Sirous, Simone Brogi, Vincenzo Calderone
Structure-Based High-Throughput Virtual Screening and Molecular Dynamics Simulation for the Discovery of Novel SARS-CoV-2 NSP3 Mac1 Domain Inhibitors. Viruses 15 (12) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry (2023)
Behnaz Yazdani, Hajar Sirous, Simone Brogi, Vincenzo Calderone
Structure-Based High-Throughput Virtual Screening and Molecular Dynamics Simulation for the Discovery of Novel SARS-CoV-2 NSP3 Mac1 Domain Inhibitors. Viruses 15 (12) (2023)
Behnaz Yazdani, Hajar Sirous, Simone Brogi, Vincenzo Calderone
Structure-Based High-Throughput Virtual Screening and Molecular Dynamics Simulation for the Discovery of Novel SARS-CoV-2 NSP3 Mac1 Domain Inhibitors. Viruses 15 (12) (2023)
Lorenzo Flori, Simone Brogi, Hajar Sirous, Vincenzo Calderone
Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes. International journal of molecular sciences 24 (8) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Simone Brogi, Hajar Sirous, Vincenzo Calderone, Giulia Chemi
Amyloid β fibril disruption by oleuropein aglycone: long-time molecular dynamics simulation to gain insight into the mechanism of action of this polyphenol from extra virgin olive oil. Food & function 11 (9) (2021)
Hajar Sirous, Giuseppe Campiani, Simone Brogi, Vincenzo Calderone, Giulia Chemi
Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors. Molecules (Basel, Switzerland) 25 (8) (2020)

Hajar Sirous.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hajar Sirous